Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs BlackRock TCP Capital Corp — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.63 (market cap $58.74B), while BlackRock TCP Capital Corp trades at $3.99 (market cap $337.71M). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 173.9× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (18.88%). Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days and BlackRock TCP Capital Corp for 88 Days on average.
| TAK | TCPC | |
|---|---|---|
Market Cap | $58.74B | $337.71M |
Volume | 3,110,994 | 436,109 |
Sector | Health | Financials |
52-Week High | $19.05 | $6.20 |
52-Week Low | $13.23 | $3.13 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $86.65B | $1.09B |
Dividend Yield | 3.33% | 18.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TCPC trades at $4.01, up 1.78% today, with a bullish technical signal from moving averages. The company reported Q2 2026 earnings of $0.22 per share, beating expectations, and announced a $523 million portfolio sale to reduce leverage. However, revenue and net income remain negative, with a net income margin of 118.75% in 2026 indicating significant losses relative to revenue. The stock is trading below book value with a P/B of 0.61.
The outlook is mixed: strategic actions like portfolio sales may improve financial health, but persistent negative earnings and a class action lawsuit pose risks. Analyst sentiment is cautious with a 30.77% buy rating. Investors should weigh the potential for operational turnaround against ongoing profitability challenges and legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
